medigraphic.com
Colegio de Medicina Interna de México.

2006, Number 1

<< Back Next >>

Med Int Mex 2006; 22 (1)

Latent tuberculosis infection in patients with rheumatoid arthritis

Esquivel MCG, Velasco RVM, Guzmán SS, Luna BJD, Borbón RR, Jacobo ÁA

Language: Spanish
References: 33
Page: 3-9
PDF size: 216.77 Kb.


ABSTRACT

Background: Tuberculosis can appear as a disease with manifestations to target organs, mainly the lung (82.2%), and as a latent tuberculosis infection. Rheumatoid arthritis patients, those with an articular chronic infl ammation, and those with immunosuppressive treatments and with tumor necrosis factor inhibitors are susceptible to catch the disease. Tuberculin test is an important part in the prophylactic treatment of it.
Objective: To determine the prevalence of the purifi ed protein derivative (ppD) in rheumatoid arthritis, the amplifi ed effect, and the risk factors for a positive ppD skin test.
Patients and method: We included 112 patients with rheumatoid arthritis. A crossover study was done at the unidad médica de alta especialidad número 134 del imss from torreón, coahuila, mexico. We applied them the tuberculin test with the mantoux method. The reading was done between 48 and 72 hours after the application. We considered positive an induration ≥ 5 mm.
Results: The latent tuberculosis infection prevalence, as well as that of the positive ppD in heumatoid arthritis was of 16.96 per 100,000 inhabitants, whereas the prevalence of the amplifi cation or booster effect was of 10.7 per 100,000 inhabitants. The prevalence of the initial positive ppD and that of the booster was of 25.89 per 100,000 inhabitants. Significant variables were: alcoholism (or = 2.37 p = 0.026), and hemoglobin ‹ 10 g/dl (or = 1.9; p = 0.066).
conclusions: The prevalence of the measurement of skin tuberculin reaction is similar to that of the tuberculosis.


REFERENCES

  1. World Health Organization Global Tuberculosis control WHO Report 2001. WHO/CDC/TB/2001. 287 Geneva, Switzerland WHO, 2001.

  2. A merican Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.

  3. N olte FS, Metckek B. Mycobacterium. Manual of clinical microbiology. 6th ed. Washington: ASM Press, 1995;pp:400-37.

  4. P érez-Guzmán C, Torres-Cruz A, Quiñones-Falconi, Villarreal-Velarde H, et al. Tuberculosis drogorresistente. Algunas consideraciones clínicas. Rev Int Nal Enf Resp Mex 1999;12:143-7.

  5. R aviglione MC , Zinder DE Jr, Kochi A. Global epidemiology of tuberculosis: morbility and mortality of a worldwide epidemic. JAMA 1995;273:220-6.

  6. División técnica de información estadística en salud. El IMSS en cifras en la población derechohabiente. 2003. Rev Med IMS 2004;42(4):353-64.

  7. T orres-Cosme JL. Panorama de la tuberculosis. Epidemiología. Sistema Nacional de Vigilancia Epidemiológica. Sistema único de información 1995;12:1-2.

  8. T apia-Conyer R, Ruiz-Mata C, Ferreira-Guerrero E, Sada-Díaz, Sifuentes-Osornio J. Temas de medicina interna. Tuberculosis: epidemiología de la tuberculosis en México. Asociación de Medicina Interna de México. México: Interamericana McGraw-Hill, 1995;pp:762-6.

  9. M andel GL, Petri WA Jr. Chemotherapy in microbial disease. In: Hardam JG, Limbrid LE , Molinoff PB, Ruddon RW, Goodman GA, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996;pp:1225-46.

  10. P inna D. Algunas consideraciones respecto al test de tuberculina (PP ). Servicio de clínica médica. Hospital privado de comunidad. Córdoba 4545(B7602CBM) Mar del Plata argentina. www.boletinepidemiologico.gov.ar

  11. L ee E, Holzman R. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-70.

  12. C ardona P-J, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis latent bacilli. Eur Respir J 2004;24:1044-51.

  13. Gardam M, Iverson K. Rheumatoid arthritis and tuberculosis: time to take notice. J Rheumatol 2003;30(7):1397-9.

  14. C armona L, Hernandez-Garcia, Vadillo C. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1736-9.

  15. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44:S105.

  16. T errazas Estrada JJ. Tuberculosis pulmonar. En: Arredondo JL, Figueroa Damián R. Temas actuales en infectología. México, Intersistemas Editores, 2000;pp:47-56.

  17. Williams EA , Fye KH. Rheumatoid arthritis. Targeted interventions can minimize joint destruction. Postgraduate Med 2003;114(5):19-28.

  18. Haraqui B, Keystone EC , Thorne JC, Pope JE, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31(12):2356-9.

  19. Jasmer RM , Nahid P, Hopewell PC . Latent tuberculosis infection. N Engl J Med 2002;347(23):1860-6.

  20. Furst DE, Cush J, Kaufman S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients whit rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61(Suppl 3):ii62-63.

  21. Furst DE, Breedveld FC, Kalden JR, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory disease (May 2003). Ann Rheum Dis 2003;62(Suppl II ): ii2-ii9.

  22. TU BERSOL ® derivado proteínico de tuberculina (Mantoux). Información para prescribir amplia. file:///C|/documents%20Settings/Propietari...escribir/aventis/Aventis_prescribir/TU BERSOL .htm

  23. Velasco RVM, Martínez OVA, Padua GA, Lazo-Sáenz JG, Cicero-Sabido R. Utilidad de la prueba cutánea a la coccidioidina en personas con diabetes mellitus tipo 2 en una zona endémica. Rev Invest Clin 2001;53(3):223-7.

  24. Velasco RVM, Padua GA, Esquivel MC , Sánchez CO , et al. Epidemiología y resistencia primaria a fármacos en casos incidentes de tuberculosis pulmonar. Rev Med IMS 2004;42(4):303-8.

  25. I nstituto Nacional de Estadística, Geografía e Informática. Estadística del Sector Salud y Seguridad Social. Cuaderno 18. México: INE GI, 2001.

  26. R ivera-Márquez V, Chávez-Pérez N, Hernández-Vásquez R, Partela-Hernández M, et al. PP D en pacientes con artritis reumatoide (AR ) y lupus eritematoso sistémico (LES ). Revista de Dermatología 2004;19(1):25.

  27. T issot F, Zanetti G, Francioli P, Zellweger J-P, Zisset F. Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005;40:211-9.

  28. S antisteban Sánchez C, Urquiza Álvarez J, Núñez Ramírez M, Hernández Mariño LA , Díaz Motas MM . Factores asociados a la tuberculosis en el Municipio Manzanillo período 1997-2000 http://wwwmonografias.com/trabajos14/tuberculosis/tuberculosis. shtml#RESUM

  29. A ndrews NC . Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251-2.

  30. R iley RL , Mills CC , O’Grady F, et al. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infectiousness of different patients. Am Rev Respir Dis 1962;85:511.

  31. Dannenberg AM Jr. Delayed type hypersensitivity and cell mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991;12:7.

  32. R ich EA , Panuska JR, Wallis RS , et al. Dyscrodinate expression of tumor necrosis factor alpha by human blood monocytes and alveolar macrophages. Am Rev Respir Dis 1989;139:1010.

  33. S ecretaría de Salud. Norma oficial mexicana: modificación NOM -006-SSA 2-1993 para la prevención y control de la tuberculosis en la atención primaria de la salud. Diario Oficial de la Federación 2000;18:9-33.




2020     |     www.medigraphic.com